New study on preeclampsia confirms effectiveness of screening in Spain

Multicenter study PRE/REDUCEDunder the guidance of the gynecology and obstetrics service University Hospital of TorrejonAnd iMaterna Foundationapproved basic methods preeclampsia screening among the Spanish population with the aim of providing preventive treatment among high-risk populations and thus avoiding its occurrence.

In particular, preeclampsia affects 23% pregnancies, being one of the most serious complications during pregnancy. This disease consists of high blood pressure from the mother, which can reduce the flow of blood, oxygen and nutrients to the fetus and cause growth problems, premature birth and even death.

In the case of the mother, it is one of the leading causes of maternal mortality during pregnancy, and its effects can continue after birth, with an increased risk of cardiovascular disease in women suffering from it.

“In high-risk women, low-dose aspirin is a safe treatment during pregnancy and has been shown to reduce the incidence of the disease in clinical studies.”

“The most significant institution in the field of maternal-fetal medicine research, Fetal Medicine Foundationdeveloped a screening system capable of identifying women at increased risk of developing preeclampsia in the first trimester and, in addition, demonstrated the existence of preventive treatment in these cases. In the first phase of the PREVAL study, we showed that this screening method also works in our population by analyzing 10,110 pregnancies from 2017 to 2019.. Using the data obtained, we adapted this model to our system to identify those patients who would benefit from aspirin use in reducing morbidity,” indicates Dr. Mar Gil

Research Coordinator of the Department of Fetal and Fetal Medicine, University Hospital of Torrejon.

From the outside Dr. Belen SantacruzHead of the Gynecology and Obstetrics Service at the University Hospital of Torrejon, emphasizes that the study is currently under development. clinical implementation stage which involves screening an additional 10,000 pregnant women to demonstrate that the treatment actually reduces the rate of preterm preeclampsia. “In women at high risk taking aspirin In low doses, it is a safe treatment during pregnancy and has been shown to reduce the incidence of the disease in clinical studies; We now hope that our research will make it easier for health authorities to implement this idea. important national selection“, Add.

The Spanish Society of Gynecology and Obstetrics, the largest scientific conference in this field held in Spain, recognized and awarded the PREVAL study in its 37th edition of the National Congress. Gynecologists, obstetricians and other experts and researchers elevated the results into a presentation and presented a prize for the best communication of the Congress.